1. Home
  2. RDVT vs CTMX Comparison

RDVT vs CTMX Comparison

Compare RDVT & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Red Violet Inc.

RDVT

Red Violet Inc.

HOLD

Current Price

$69.28

Market Cap

793.2M

Sector

Technology

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$3.80

Market Cap

642.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDVT
CTMX
Founded
2017
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
793.2M
642.2M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
RDVT
CTMX
Price
$69.28
$3.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
10
Target Price
$62.00
$12.10
AVG Volume (30 Days)
160.0K
5.5M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
82.00
N/A
EPS
0.30
N/A
Revenue
$90,252,000.00
$76,201,000.00
Revenue This Year
$16.31
N/A
Revenue Next Year
$13.83
$7.61
P/E Ratio
$218.40
$22.58
Revenue Growth
20.03
N/A
52 Week Low
$33.40
$1.72
52 Week High
$67.68
$8.21

Technical Indicators

Market Signals
Indicator
RDVT
CTMX
Relative Strength Index (RSI) 82.15 62.72
Support Level $50.66 $3.76
Resistance Level N/A $3.90
Average True Range (ATR) 2.66 0.22
MACD 0.97 0.12
Stochastic Oscillator 96.04 90.34

Price Performance

Historical Comparison
RDVT
CTMX

About RDVT Red Violet Inc.

Red Violet Inc builds proprietary technologies and applies analytical capabilities to deliver identity intelligence. The company's solutions enable the real-time identification and location of people, businesses, assets, and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Its cloud-native, AI-enabled identity intelligence platform, CORE, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. The company generates substantially all of its revenue from licensing its solutions.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: